Dbv Technologies S.A.: 5%+ holders

Dbv Technologies S.A. has 25 Schedule 13D or 13G filings on record since 2025-08-12. 6 holders' latest filing reports 5% or more of ordinary shares, nominal value 0.10 euro per share. Each figure below is the holder's own, as filed, with the filing linked.

Holders

Purpose of Transaction (Item 4)

Bpifrance Participations S.A.

Item 4 of the Schedule 13D is hereby amended and supplemented as follows: Bpifrance Participations sold the amount of Ordinary Shares on the date and at the price set forth below in open market transactions, except as noted otherwise. The sales of the Ordinary Shares were sold in multiple transactions at varying prices. The Reporting Persons undertake to provide the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each price within the ranges set forth in this Schedule 13D. January 5, 2026: - 86,777 Ordinary Shares at a weighted average price of EUR3.02 per share (multiple transactions at prices ranging from EUR2.92 to EUR3.19, inclusive). All of the Ordinary Shares that are held of record by the Reporting Persons as reported herein were acquired for investment purposes. The Reporting Persons retain the right to change their investment intent, from time to time to acquire additional Ordinary Shares or other securities of the Issuer, or to sell or otherwise dispose of all or part of the Ordinary Shares or other securities of the Issuer, if any, beneficially owned by them, in any manner permitted by law. The Reporting Persons may engage from time to time in ordinary course transactions with financial institutions with respect to the securities described herein. Except as set forth above, none of the Reporting Persons currently has any plans or proposals …The first part of Item 4 of the SCHEDULE 13D/A filed 2026-01-07; the filing has the rest

Baker Bros. Advisors LP

Item 4 of Schedule 13D is supplemented and amended, as the case may be, as follows: On January 12, 2026, 667 and Life Sciences exercised 2,299,656 and 25,005,240 warrants, respectively, (each, a "BS Warrant") of the Issuer, at a strike price of EUR 1.5764, on a one-for-one basis into pre-funded warrants (each, a "Second Pre-Funded Warrant"), each of which are exercisable for 1.75 Ordinary Shares of the Issuer at an exercise price of EUR 0.0175. The BS Warrants were exercisable until January 15, 2026, which is 30 days following the publication by the Issuer that the VITESSE Phase 3 study met its primary endpoint as further described in the Terms and Conditions of the BS Warrants. Each of the Funds paid the exercise price for the BS Warrants using its working capital. The Second Pre-Funded Warrants bear an unpaid exercise price per Ordinary Share issuable pursuant to such Second Pre-Funded Warrants (a "Second Pre-Funded Warrant Share") of EUR 0.01. The Second Pre-Funded Warrants may be exercised until April 7, 2035. The Funds hold securities of the Issuer for investment purposes. The Reporting Persons or their affiliates may purchase additional securities or dispose of securities in varying amounts and at varying times depending upon the Reporting Persons' continuing assessments of pertinent factors, including the availability of Ordinary Shares, ADS or other securities for purchase at particular price levels, the business prospects of the Issuer, other business investment …The first part of Item 4 of the SCHEDULE 13D/A filed 2026-01-14; the filing has the rest

Timeline

Where this comes from

Anyone who comes to own more than 5% of a class of a listed company's voting shares has to tell the SEC. A holder who may seek to change or influence the company files Schedule 13D, and has to say in Item 4, "Purpose of Transaction", what it intends to do. A holder with no such intent, such as many index and passive funds, may file the shorter Schedule 13G. Both are amended when the stake changes, including when it falls below 5%.

Every row here is one of those filings, linked to the filing itself. Percentages and share counts are exactly as the holder filed them, for the holder the filing names; an amendment showing a lower figure is shown as filed. Item 4 text is quoted word for word. Where a 13D's Item 4 contains a sentence stating a definite intent to influence the company, that sentence is marked and quoted; the page does not describe the holder or its motives beyond the words it filed. Nothing here is investment advice.

All recent stakesThat week's stakes